‘Discontinuation Of Therapy in Multiple Sclerosis’ selected as JAMA Editor’s Choice: Clinical Trial of 2025The study Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis has been selected by the Editor of JAMA Neurology as an Editor’s Choice: Clinical Trials of 2025. This is a special honor for principal investigator and neurologist Eva Strijbis, PhD candidates Wing Hee Fung and Eline Coerver, and the rest of the research team at the MS Center Amsterdam.
Phase 3 trial shows a reduction in recurrent ischemic strokeResearchers at Amsterdam UMC, in collaboration with colleagues worldwide, have shown in a phase 3 clinical trial that a new blood-thinning medication, asundexian, reduces the risk of a new stroke by approximately 25%. Importantly, the drug did not cause an increase in severe bleeding, which is a known side effect of potent blood thinners.
ZonMw awards highlight the strength of the collaboration between VU and Amsterdam UMC in Alzheimer’s drug discoveryIn total, six projects have received a ZonMw award within the Promising Innovative Therapies program. This program supports the development of new treatments targeting the underlying mechanisms of dementia, intending to accelerate their progression towards clinical application. The projects within Amsterdam Neuroscience explore a range of approaches to treating Alzheimer’s disease, from drug development to brain stimulation and gene therapies.
